- St. Jude Medical has received U.S. FDA approval for its Axium Neurostimulator for dorsal root ganglion stimulation
- The device helps treat chronic intractable pain of the lower limbs in adult patients with complex regional pain syndrome by stimulating the dorsal root ganglion – a cluster of nerve cell bodies in a posterior root of a spinal nerve
- “The approval of St. Jude Medical’s DRG neurostimulation system represents an exciting new option for me to deploy in the fight against the focal and intractable chronic pain syndromes facing my patients every day,” said Dr. Timothy Deer
St. Jude Medical, a global medical device company, has received U.S. FDA approval for its Axium Neurostimulator for dorsal root ganglion (DRG) stimulation. The firm in a press release said that the approval would ensure access to a better therapeutic approach for treating mild to severe chronic intractable pain of the lower limbs in adults patients with complex regional pain syndrome.
The DRG is an effective target to stimulate electrically due its particular position and sensory nerve density. Signals from the lower limbs pass through the ganglion and toward the brain, so the firm considers clinicians will have better options to target different pain sources. Officials with the company confirmed that the technology would be made available to physicians and patients in the coming months.
“The approval of St. Jude Medical’s DRG neurostimulation system represents an exciting new option for me to deploy in the fight against the focal and intractable chronic pain syndromes facing my patients every day,” said Dr. Timothy Deer, an interventional pain physician, president and CEO of the Center for Pain Relief in Charleston, West Virginia. “For the large and growing numbers of under-treated patients suffering from complex regional pain syndromes – like those resulting from total knee arthroscopy, foot surgery or hernia surgery – DRG stimulation can offer improved, long-lasting relief.”
Allen Burton, M.D., medical director of neuromodulation and vice president of medical affairs at St. Jude Medical, said that “St. Jude Medical is focused on providing physicians with more options to treat patients suffering from a wide range of chronic pain conditions, no matter where in the body the patient may experience pain. The addition of DRG stimulation to our portfolio demonstrates our continued commitment to ensuring physicians have the broadest range of meaningful chronic pain therapy options.”
The Axium system received CE Mark in 2011 for the management of chronic intractable pain. The system is also approved for use in Australia.
Visit the source page: St. Jude Medical